IL6 and acute myeloid leukemia: This drug blocks JAK/STAT signaling activated by MSC-derived cytokines, such as IL-6, and is currently under a phase I/II clinical trial for post-myeloproliferative neoplasm secondary AML to evaluate its therapeutic efficacy in combination with decitabine (NCT03558607).